omadacycline UTI
Selected indexed studies
- In vitro activity of omadacycline and levofloxacin against Escherichia coli, Klebsiella pneumoniae and Staphylococcus saprophyticus in human urine supplemented with calcium and magnesium. (J Antimicrob Chemother, 2020) [PMID:32428235]
- In Vitro Activity of Omadacycline and Comparator Antibiotics against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Urinary Isolates. (Antibiotics (Basel), 2023) [PMID:37370272]
- Efficacy of Omadacycline against Escherichia coli in a Mouse Urinary Tract Infection Model. (Antimicrob Agents Chemother, 2021) [PMID:33972239]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- In vitro activity of omadacycline and levofloxacin against Escherichia coli, Klebsiella pneumoniae and Staphylococcus saprophyticus in human urine supplemented with calcium and magnesium. (2020) pubmed
- In Vitro Activity of Omadacycline and Comparator Antibiotics against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Urinary Isolates. (2023) pubmed
- Efficacy of Omadacycline against Escherichia coli in a Mouse Urinary Tract Infection Model. (2021) pubmed
- In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. (2014) pubmed
- Susceptibility of multidrug-resistant Escherichia coli and Klebsiella pneumoniae to oral antibiotics in Australia. (2025) pubmed
- Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014). (2018) pubmed
- Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1b Study. (2019) pubmed